Nearly 250,000 people in England could be taking Eli Lilly & Co.’s blockbuster weight-loss drug Mounjaro within three years as part of a phased rollout of the popular drug.

BMO Capital Markets analyst Evan Seigerman called it “another positive indication” for Eli Lilly, whose top-selling diabetes ...

Viking Therapeutics, Inc.'s stock surged 1,500% on the promising obesity drug VK-2735, with Phase 3 trials and potential for ...

A study from tirzepatide's manufacturer found that the GLP-1 drug could significantly improve heart failure symptoms.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

There are several Ozempic alternatives available today, like Rybelsus, Mounjaro, Wegovy and Zepbound. Other medications may ...

In the 176-week study run over three years – which underpinned tirzepatide's approval for obesity last year – once-weekly injections of tirzepatide at three dose levels – 5, 10, and 15 mg ...

It's hard to overstate just how successful weight-management treatments have been over the past couple of years. Sales of semaglutide, the drug that Novo Nordisk (NYSE: NVO) markets as Ozempic and ...